Abstract: A hydraulic regenerative braking system is provided for using hydraulic fluid to capture energy from a vehicle during a braking event. The system captures kinetic energy from a shaft of the vehicle and stores the kinetic energy as hydraulic potential energy. That is, the system captures rotational energy as hydraulic potential energy in an accumulator. The hydraulic regenerative braking system also discharges the hydraulic potential energy as kinetic energy. During braking, kinetic energy is transferred from the vehicle shaft to a gearbox, and from the gearbox to a hydraulic pump. The hydraulic pump uses the kinetic energy to pump hydraulic fluid to an accumulator, increasing the hydraulic potential energy stored in the accumulator. During driving, the hydraulic fluid is released from the accumulator to the hydraulic pump, generating kinetic energy that is transferred to the vehicle shaft via the gearbox.

Abstract: The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the ?-III isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.

Abstract: The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the ?-III isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.

Abstract: A hydraulic hybrid system for implementation in a machine. The system includes a hydraulic system, an energy source, an output, and a transmission. The hydraulic system includes a primary hydraulic pump/motor (primary motor) that is hydraulically coupled to a reservoir and a variable-volume accumulator assembly. The primary motor is configured to charge an accumulator of the variable-volume accumulator assembly with a working fluid when mechanically driven. The storage volume of variable-volume accumulator assembly varies based on a kinetic output condition of the machine. The energy source is configured to produce primary kinetic energy. The output is configured to receive at least a first portion of the primary kinetic energy. The transmission is coupled between the energy source and the output and selectively coupled to the primary motor. The transmission is configured to mechanically drive the primary motor using a second portion of the primary kinetic energy.

Abstract: An example embodiment includes a hydraulic hybrid system. The hydraulic hybrid system includes a hydraulic system, an energy source configured to produce primary kinetic energy, an output configured to receive at least a first portion of the primary kinetic energy, and a transmission coupled between the energy source and the output and selectively coupled to the hydraulic system. The hydraulic system includes a reservoir, a sequenced accumulator assembly, and a hydraulic pump/motor that is hydraulically coupled to the reservoir and the sequenced accumulator assembly and configured to charge the sequenced accumulator assembly when mechanically driven. The sequenced accumulator assembly includes two or more accumulators, one or more sequence valves, and one or more check valves. The sequenced accumulator assembly is configured to store varying amounts of potential hydraulic energy by introducing and removing one or more of the accumulators from operation.

Abstract: A hydraulic hybrid system for implementation in a machine. The system includes a hydraulic system, an energy source, an output, and a transmission. The hydraulic system includes a primary hydraulic pump/motor (primary motor) that is hydraulically coupled to a reservoir and a variable-volume accumulator assembly. The primary motor is configured to charge an accumulator of the variable-volume accumulator assembly with a working fluid when mechanically driven. The storage volume of variable-volume accumulator assembly varies based on a kinetic output condition of the machine. The energy source is configured to produce primary kinetic energy. The output is configured to receive at least a first portion of the primary kinetic energy. The transmission is coupled between the energy source and the output and selectively coupled to the primary motor. The transmission is configured to mechanically drive the primary motor using a second portion of the primary kinetic energy.

Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.

Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.

Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.

Abstract: Bis-sulfonamido hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease inhibiting compounds of the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the variables are as defined herein.

Abstract: Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Abstract: Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Abstract: A probucol or a probucol derivative can be efficiently converted to a monoester or monoether of probucol by reacting the free hydroxyl-containing probucol or a derivative thereof (by which is meant a probucol compound with at least one substituent that is different from that on the parent probucol molecule but which maintains the two free hydroxyl groups) with a Grignard reagent or a lithium reagent that produces a magnesium bromide or lithium salt of probucol or the probucol derivative. The probucol compound anion anion is then reacted with an ester or ether forming compound.

Abstract: Bis-sulfonamido hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease inhibiting compounds of the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the variables are as defined herein.

Abstract: A probucol or a probucol derivative can be efficiently converted to a monoester or monoether of probucol by reacting the free hydroxyl-containing probucol or a derivative thereof (by which is meant a probucol compound with at least one substituent that is different from that on the parent probucol molecule but which maintains the two free hydroxyl groups) with a Grignard reagent or a lithium reagent that produces a magnesium bromide or lithium salt of probucol or the probucol derivative. The probucol compound anion anion is then reacted with an ester or ether forming compound.

Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.

Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.

Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.

Abstract: The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

Abstract: The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.